Glucoris M2 Tablet PR contains a combination of Glimepiride (2mg) and Metformin (500mg), formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby enhancing glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. This dual-action formulation provides complementary mechanisms to effectively lower blood glucose levels in patients inadequately controlled by diet and exercise alone. Glucoris M2 Tablet PR is indicated for adult patients with type 2 diabetes who require combination therapy to achieve optimal glycemic targets. The prolonged-release formulation ensures a steady release of active ingredients, promoting improved patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. It is essential to monitor renal function prior to and during treatment, as metformin is contraindicated in patients with significant renal impairment. Dose adjustments may be necessary based on glycemic response and tolerability. Glucoris M2 Tablet PR should be used alongside lifestyle modifications, including diet and exercise, to maximize therapeutic outcomes. Patients should be advised regarding the signs of hypoglycemia and the importance of adherence to prescribed regimens.